Spanish Pharma Stock News

Iberpapel Gestión (BME:IBG) has opened 2026 with investors looking closely at how its latest Q1 figures sit against a year of modest revenue growth and thinner margins, after trailing twelve month revenue was €217.1 million and net income was €6.1 million at the end of Q4 2025. Over recent quarters the company has seen quarterly revenue move from €57.4 million in Q4 2024 to €65.8 million in Q1 2025 and €51.5 million in Q4 2025, while basic EPS shifted from €0.70 in Q4 2024 to €0.10 in Q2 2025...

Redeia Corporación (BME:RED) has opened 2026 with Q1 revenue of €461.4 million and net income of €140.3 million, translating into basic EPS of €0.26. The company has seen quarterly revenue move from €418.9 million in Q1 2025 to €461.4 million in Q1 2026, while trailing twelve month revenue sits at about €1.75 billion and TTM EPS at €0.91. This sets the scene for investors to weigh modest growth expectations against a net margin that has eased from 30.9% to 28% over the last year, as well as a...

The European market has recently faced challenges, with the pan-European STOXX Europe 600 Index declining by 2.54% amid geopolitical tensions and economic uncertainties. For those looking to invest in smaller or newer companies, penny stocks—despite the name's vintage feel—can still offer surprising value. In this article, we explore three European penny stocks that demonstrate financial strength and potential for long-term growth, providing investors with an opportunity to uncover hidden...

US infrastructure win puts Acciona (BME:ANA) in focus Acciona (BME:ANA) has come into focus after its construction arm, within the FlatironDragados consortium, was chosen to help build tolled express lanes on Georgia’s State Route 400 under a public private partnership. The project, backed by government loans and private activity bonds, adds another reference contract to Acciona’s international infrastructure portfolio. This portfolio spans roads, water solutions, renewable energy assets, and...

Mapfre (BME:MAP) has just opened Q1 2026 earnings season with a backdrop of solid prior-year numbers, including €11.3b in Q4 2025 revenue and net income of €303.6m, alongside trailing 12 month EPS of €0.37 on revenue of about €30.0b. Over the last reported quarters, revenue has ranged from €4.5b in Q3 2025 to €11.3b in Q4 2025, with quarterly net income between €192m and €320m and EPS ticking around the €0.10 mark, giving you a clear line of sight on how the business has been converting top...

Banco Santander (BME:SAN) has just posted Q1 2026 numbers with total revenue of €12.2b and basic EPS of €0.23, giving investors fresh data on both top line activity and earnings power. Over recent quarters, revenue has moved between €11.2b in Q3 2025 and €13.4b in Q4 2024 while basic EPS has ranged from €0.17 in Q4 2024 to €0.23 in Q1 2026, setting a clear earnings backdrop for today’s release. With net profit margins improving over the last year and trailing twelve month EPS at €0.85, the...

Q1 2026 earnings snapshot for Naturgy Energy Group (BME:NTGY) Naturgy Energy Group (BME:NTGY) has entered Q1 2026 off the back of Q4 2025 revenue of €4.9b and net income of €355m, with Basic EPS at €0.38. Over recent quarters the company has seen quarterly revenue range between €4.5b and €5.3b. Basic EPS moved from €0.33 in Q4 2024 to €0.55 in Q2 2025 and €0.38 in Q4 2025. This has taken place against a backdrop of trailing net margins around 10.4% compared with 10% a year earlier, so the...

Sacyr (BME:SCYR) has opened Q1 2026 earnings season with investors focused on how its recent revenue and EPS trends square with a share price of €4.678 and a trailing twelve month net income of €85.8 million on €4.7 billion of revenue at the end of 2025. Over recent quarters, revenue has moved from €1,059.0 million in Q1 2025 to €1,178.6 million in Q2, €1,174.2 million in Q3 and €1,251.5 million in Q4. Over the same period, quarterly basic EPS shifted from €0.0047 in Q2 2025 to €0.0298 in Q4,...

Cellnex Telecom (BME:CLNX) has come into focus after reporting first quarter 2026 results, with sales of €984 million and a net loss of €37 million, compared with €964 million and a €49 million loss a year earlier. See our latest analysis for Cellnex Telecom. Cellnex Telecom’s latest share price of €28.62 follows a Q1 earnings update and coincides with a 3.21% 1-month share price return and a 9.99% 3-month share price return. The 1-year total shareholder return of an 18.54% decline indicates...

Iberdrola (BME:IBE) has just opened 2026 earnings season with Q1 numbers that cap a busy 2025, reporting quarterly revenue of about €11.7b and basic EPS of €0.14, compared with trailing 12 month revenue of €44.1b and EPS of €0.85. The company reported revenue of €12.9b in Q1 2025 and €11.7b in Q4 2025, while quarterly EPS moved from €0.31 to €0.14 over the same period. This gives investors a clearer view of how reported growth of 45.4% over the past year and a net margin of 12.9% are...

Aena S.M.E (BME:AENA) has just posted its Q1 2026 scorecard, with recent quarterly revenue sitting at about €1.6b in Q4 2025 and Basic EPS at €0.37, against a trailing twelve month EPS of €1.42 on revenue of €6.3b. Over recent quarters the company has seen revenue move from €1.4b in Q4 2024 to €1.6b in Q4 2025, while quarterly EPS has ranged between €0.20 and €0.46. This sets up the latest release as a check in on how consistently Aena is converting its traffic and fee streams into earnings...

Banco Santander reported record quarterly profits, supported by a substantial gain from the sale of Santander Bank Polska. The group announced a multi billion euro share buyback program alongside these results. Regulators have cleared Banco Santander to proceed with its planned acquisition of UK based TSB, which the bank now expects to complete shortly. The recent moves put Banco Santander (BME:SAN) firmly in focus for investors watching large European banks. The shares last closed at...

Telefónica stock snapshot after recent performance shift Telefónica (BME:TEF) has drawn fresh attention after a recent share price move, with the stock showing mixed returns over different periods that may prompt investors to reassess its risk and reward profile. See our latest analysis for Telefónica. Despite a 2.0% 1 day share price decline and a 2.2% 7 day share price return, Telefónica’s 30 day and 90 day share price returns of 3.4% and 13.5% suggest momentum has recently been building...

Santander (BME:SAN) is back in focus after agreeing to pay compensation under the UK Financial Conduct Authority’s redress scheme for unfair motor finance deals, opting to implement the payments rather than challenge the regulator. See our latest analysis for Banco Santander. The latest compensation decision comes after a mixed spell for the stock, with a 9.3% 1 month share price return alongside a 4.8% 3 month share price decline. However, a very large 5 year total shareholder return...

While Solaria Energía y Medio Ambiente, S.A. ( BME:SLR ) might not have the largest market cap around , it saw a...

Why Amadeus IT Group Is Back on Investors’ Radar Amadeus IT Group (BME:AMS) has drawn fresh attention after a period of mixed share performance, with recent moves in the price inviting closer scrutiny of its valuation and business fundamentals. See our latest analysis for Amadeus IT Group. The latest 1-day share price return of 2.14% decline and 7-day share price return of 4.94% decline fit into a weaker pattern, with year-to-date share price return of 20.52% decline and 1-year total...

Grifols (BME:GRF) reported proof of concept data from its Chronos-PD program. The company found molecular changes linked to Parkinson’s disease in blood plasma. These changes were detected up to 12 years before clinical diagnosis. Grifols, best known for its plasma derived therapies and diagnostic products, is extending that expertise into neurology with Chronos-PD. The early Parkinson’s signal in plasma connects directly to the company’s existing strengths in blood based testing, an area...

Wondering whether Repsol's current share price truly reflects its underlying worth, or if the market is missing something that you should not. Repsol shares last closed at €21.23, with returns of 3.5% over 7 days, a 6.4% decline over 30 days, 29.4% year to date, 114.8% over 1 year, 81.8% over 3 years and 164.5% over 5 years. Recent coverage has focused on Repsol's position as a major integrated energy player and how investor attention on the sector has shifted in light of energy pricing and...

Enagás (BME:ENG) opened 2026 with Q1 revenue of €227.4 million and net income of €56.9 million, equal to basic EPS of €0.22, setting a measured tone for investors watching how the story evolves after a volatile few years. The company has seen quarterly revenue move from €203.4 million in Q1 2025 to €227.4 million in Q1 2026, while trailing twelve month revenue sits at €977.7 million and trailing EPS at €1.27, giving you a clearer read on how top and bottom line have settled recently. Overall,...

As European markets show resilience with the STOXX Europe 600 Index rising by 1.91% amid positive corporate earnings and geopolitical de-escalation, investors are increasingly looking towards small-cap stocks for potential opportunities. In this environment, identifying promising companies like Cox ABG Group and other lesser-known European small caps involves evaluating their growth potential, financial health, and ability to adapt to changing economic conditions.

While Fomento de Construcciones y Contratas, S.A. ( BME:FCC ) might not have the largest market cap around , it saw...

Iberdrola recently reported on its latest shareholder and analyst call that installed power production capacity reached 58,877 MW by the end of the first quarter, a 3.8% year-on-year increase driven by expansions in the United States, Spain, Australia and other European markets. The company also highlighted very large growth in battery energy storage to 683 MW, underlining how fast storage is becoming a more central part of its renewable asset base. Next, we will examine how this rapid...

Grifols (BME:GRF) has been in focus after Health Canada imposed new regulatory conditions on its paid plasma collection centers, and the company moved to refinance and repurchase parts of its debt stack. See our latest analysis for Grifols. Those refinancing steps and the Health Canada conditions arrive after a mixed run for investors, with the latest €9.646 share price sitting alongside a 30 day share price return of 10.14%, a year to date share price return of 13.84%, and a 1 year total...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Aena S.M.E...